Why Novo Nordisk Stock Tumbled on Tuesday
The Motley Fool·2025-08-26 22:23A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.Novo Nordisk (NVO -1.90%) has risen to fame and prominence with its twin drugs Wegovy and Ozempic, with the former being particularly hot since it's approved for weight loss. However, on Tuesday a powerful rival to the company reported positive top-line results for a drug that could provide very stiff competition to the Danish pharmaceutical's top medication.Investors didn't react happily to thi ...